United Therapeutics (NASDAQ:UTHR) Given New $660.00 Price Target at TD Cowen

United Therapeutics (NASDAQ:UTHR) had its price objective hoisted by TD Cowen from $575.00 to $660.00 in a research report released on Monday morning,Benzinga reports. TD Cowen currently has a buy rating on the biotechnology company’s stock.

Several other equities research analysts have also recently issued reports on the stock. HC Wainwright raised their target price on shares of United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Royal Bank Of Canada upped their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Finally, Bank of America restated a “neutral” rating on shares of United Therapeutics in a report on Wednesday, February 25th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $557.64.

United Therapeutics Trading Up 12.5%

United Therapeutics stock opened at $588.36 on Monday. The stock has a fifty day moving average price of $498.42 and a 200 day moving average price of $474.96. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $607.89. The firm has a market capitalization of $25.79 billion, a P/E ratio of 21.09, a PEG ratio of 1.88 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same period last year, the company earned $6.19 EPS. The firm’s quarterly revenue was up 7.4% on a year-over-year basis. As a group, equities analysts predict that United Therapeutics will post 24.48 EPS for the current year.

Insider Activity at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $489.91, for a total value of $4,654,145.00. Following the completion of the sale, the chief executive officer owned 130 shares of the company’s stock, valued at $63,688.30. This represents a 98.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $471.91, for a total transaction of $10,617,975.00. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 333,820 shares of company stock worth $165,495,478. Company insiders own 10.30% of the company’s stock.

Institutional Trading of United Therapeutics

Several large investors have recently added to or reduced their stakes in UTHR. Clearstead Advisors LLC boosted its holdings in United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 23 shares during the period. Independent Advisor Alliance increased its stake in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after purchasing an additional 27 shares during the period. Bessemer Group Inc. increased its stake in shares of United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 28 shares during the period. Florida Financial Advisors LLC lifted its position in shares of United Therapeutics by 5.4% during the 4th quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 28 shares during the last quarter. Finally, NDVR Inc. lifted its position in shares of United Therapeutics by 5.1% during the 4th quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 30 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: TETON‑1 (Tyvaso) pivotal success — the 598‑patient Phase 3 trial met its primary endpoint, showing a Hodges‑Lehmann estimate of +130.1 mL change in absolute FVC at week 52 vs. placebo, a clinically meaningful result that expands Tyvaso’s potential market beyond PAH. Read More.
• Positive Sentiment: Ralinepag Phase 3 readout + buyback momentum — investors are still digesting positive ADVANCE OUTCOMES ralinepag data (large reduction in clinical‑worsening risk) and United Therapeutics’ board authorized up to $2B in buybacks with ~$1.5B in ASRs, which accelerates share‑count reduction and supports EPS. Read More.
• Positive Sentiment: Surge in call‑option activity — unusually large options flow (≈16,800 calls, ~789% above normal) signals bullish positioning and likely amplified intraday upside through speculative buying and short‑covering. (Market data entry)
• Positive Sentiment: Analyst lift — TD Cowen raised its price target to $660 and reiterated a Buy view, which likely reinforced investor conviction after the clinical news. Read More.
• Neutral Sentiment: Read‑through to peers — some smaller respiratory/rare‑disease names saw moves on trial read‑throughs and analyst notes (e.g., Insmed), but the competitive or regulatory implications for other firms remain speculative. Read More.
• Negative Sentiment: Insider selling — CEO Martine Rothblatt sold 9,500 shares on March 26, and public filings show extensive insider sales over recent months; while not unusual for a high‑value stock, heavy insider disposals can be perceived as a headwind by some investors. Read More.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.